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Increasing numbers of laboratories develop new methods based on gas-liquid and high-
performance liquid chromatography to determine serum concentrations of oxygenated 
cholesterol metabolites such as 7α-, 24(S)-, and 27-hydroxycholesterol. We initiated a first 
international descriptive oxycholesterol (OCS) survey in 2013 and a second interventional 
survey 2014 in order to compare levels of OCS reported by different laboratories and to 
define possible sources of analytical errors. In 2013 a set of two lyophilized serum pools (A 
and B) was sent to nine laboratories in different countries for OCS measurement utilizing 
their own standard stock solutions. In 2014 eleven laboratories were requested to determine 
OCS concentrations in lyophilized pooled sera (C and D) utilizing the same provided standard 
stock solutions of OCS. The participating laboratories submitted results obtained after 
capillary gas-liquid chromatography-mass selective detection with either epicoprostanol or 
deuterium labelled sterols as internal standards and high-performance liquid chromatography 
with mass selective detection and deuterated OCS as internal standard. Each participant 
received a clear overview of the results in form of Youden-Plots and basic statistical 
evaluation in its used unit. The coefficients of variation of the concentrations obtained by all 
laboratories using their individual methods were 58.5-73.3% (survey 1), 56.8-60.3% (survey 
2); 36.2-35.8% (survey 1), 56.6-59.8, (survey 2); 61.1-197.7% (survey 1), 47.2-74.2% (survey 
2) for 24(S)-, 27-, and 7α-hydroxycholesterol, respectively. We are surprised by the very great 
differences between the laboratories, even under conditions when the same standards were 
used. The values of OCS´s must be evaluated in relation to the analytical technique used, the 
efficiency of the ample separation and the nature of the internal standard used. Quantification 
of the calibration solution and inappropriate internal standards could be identified as major 
causes for the high variance in the reported results from the different laboratories. A 
harmonisation of analytical standard methods is highly needed.   
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Ring and side-chain oxidized cholesterols or oxycholesterols (OCS) are essential transport 
forms for reverse cholesterol transport from the periphery [1,2], for cholesterol homeostasis of 
the human brain [3] and serve as precursor molecules for bile acid and steroid hormone 
synthesis [4]. Analysis of serum OCS concentrations as surrogate markers for cholesterol 
metabolism, degradation and excretion of cholesterol, allows evaluation of cholesterol 
homeostasis in the human physiology [5–7]. Detection of abnormal serum concentrations of 
OCS, combined with other indicators enables the diagnosis of certain inherited lipid storage 
diseases i.e. Nieman-Pick diseases [8–10], cerebrotendinous xanthomatosis [11] and a subtype 
of hereditary spastic paresis [12]. Therefore, reliable determination and quantification of OCS 
is essential for diagnosis and adequate patient care. During the last decades, fundamentally 
important understanding of the influence of OCS has been achieved with respect to 
development and progress of atherosclerosis [13], cardiovascular diseases [14] as well as 
neurodegenerative diseases i.e. Alzheimer disease [15]. Knowing that oxysterols may function 
as signalling molecules in cholesterol metabolism [16], makes them attractive candidates for a 
wide field of physiological actions. The ratio of the amount of plasma or CSF 24(S)-
hydroxycholesterol to 27-hydroxycholesterol is suggested to assess cholesterol metabolism in 
the brain, integrity of blood-brain barrieror to characterize pathological conditions in 
neurological disorders [17,18] (2x Leoni, clin chem. Lab 2004, J Lipid Res 2002, Björkhem I 
J Int Med] . Recently side-chain and B ring oxysterols have been identified as tumour 
promoters in several cancers or as tumour suppressors according to their structure. [19-23] 
These circumstances increase the need for analytical laboratories and research facilities to 
accurately quantify oxysterols in human serum and to develop new more accurate analytical 
procedures and methods.  
7 
 
The present international OCS survey was designed with two parts taking place in the year 
2013 and 2014. The first survey provides information about the variation of reported results 
from the different laboratories involved and was designed as “descriptive”. The second survey 
was designed as “interventional”.  
 
2. Materials and Methods 
The participants submitted results from three different separation and detection methods for 
OCS determination: capillary gas-liquid chromatography-mass selective detection using 
epicoprostanol (GC-MS-epi) or deuterated OCS (GC-MS-deuterium) as internal standard and 
high-performance-liquid-chromatography with mass selective detection (LC-MS-deuterium) 
using deuterated OCS as internal standard (Table 1). The explicit values and statistical data 
are additionally listed in Table 2. Note, 27-hydroxycholesterol is also called (25R)26-
hydroxycholesterol, taking into account stereochemistry at C-25. However, 27-
hydroxycholesterol is the more common name and will be used here. The lyophilized probes 
A-D were sent by ordinary mail with no temperature or air pressure control. This includes the 
possibility of autoxidation of cholesterol into oxysterols, which are not exclusively formed by 
enzymatic cytochrome P450 supported oxidation. One example for this could be 7α-
hydroxycholesterol, which is formed from cholesterol by both, enzymatic and radical 
oxidation. In knowledge of this fact, we limited the analysis of oxysterols to 24(S)-, 27- and 
7α-hydroxycholesterol, the first two of which are almost exclusively formed enzymatically 
[24]. [22]. The work-up procedures and analytical settings are strikingly different for each 
participant since each laboratory was requested to use its own specific routine method (Table 
1). However, each laboratory used alkaline hydrolysis in order to deconjugate fatty acid 
esterified oxysterols and thus analyzing total oxysterol serum concentrations after 
8 
 
derivatisation of the free hydroxyl groups. It should be emphasized that the individual sample 
work-up procedures or detection specifications cannot be reported within this article because 
of the anonymization of the participants. Inconsistent values are defined within the survey as 
values obtained from sample A and B concentrations which are impaired by different 
systematic errors. For example, the value for point a of sample A in Figure 1 A is slightly to 
high reported but the value of sample B is much too low determined. The participant failed to 
obtain results with the same, reproducible error. Therefore, in both samples A and B two 
different errors occurred and these inconsistent values must be regarded as failed. The ratios 
of 24(S)-hydroxycholesterol to 27-hydroxycholesterol are listed in Table 3.   
3. Statistics 
Data are given as mean ± SD. Coefficient of variation (CV), minimum and maximum values 
are also given in Table 2 for the first and second survey. The calculated statistics from all 
participants are greatly influenced by presence of single values more than 50% different from 
the calculated mean value of the submitted OCS concentrations. Such individual values were 
regarded as outliers (see Figure 1). For 7α-hydroxycholesterol selected parameters of the 
above-mentioned data were additionally calculated without the outlier values and reported 
within the manuscript (Table 2). The statistical evaluation of the data sets was weakened by 
the fact that only 13 laboratories participated, and that only eight out of 13 laboratories 
participated in both surveys.   
9 
 
4. Results  
 
4.1 First survey 
Nine laboratories specialized in chromatographic lipid analysis participated in this first 
survey. A set of two different lyophilized serum pools (sample A and B) were sent to each 
participant and analysed with the individual determination method of each laboratory. After a 
period of three months the laboratories were requested to submit their results to the 
Referenzinstitut für Bioanalytik at Bonn, Germany for further data evaluation. The data were 
given in the units individually used by the participant (ng/mL, mg/dL, µmol/L) and was 
converted into ng/mL for comparison. Each participant received his results presented in the 
form of Youden-Plots and basic statistical data. Each laboratory was informed about the 
results in the individual units, which were used by the participant. 
 
4.2 Second survey 
Eleven laboratories participated in this second survey including four laboratories that were not 
included the first survey. One group that participated in the first survey was not able to 
participate in the second survey. Two different lyophilized serum pools (sample C and D) 
were analysed by each participant. In contrast to the first part of the OCS survey the second 
part was designed as interventional, focusing on the influence of the calibration solutions 
used. Each participant was thus requested to use allocated OCS stock solutions (containing 
7α-, 24(S)-, 27-hydroxycholesterol, each 10 µg/mL) for the quantification of the lyophilized 
sample material. Data submission and notification of individual results were performed as 





In the first survey for chromatographically determined 24(S)-hydroxycholesterol nine 
different laboratories participated. The mean 24(S)-hydroxycholesterol concentration 
determined by all nine participants was calculated for sample A (61.5±36.0 ng/mL; CV 
58.5%) and B (59.0±43.3 ng/mL; CV 73.3%). One participant used the GC-MS-epi and five 
used the GC-MS-deuterium methods. Three laboratories provided results obtained from LC-
MS methods using deuterated sterols as internal standard. Two out of ten participants using  
GC-MS-deuterium and LC-MS-deuterium (Figure 1A) did not determine  
24(S)-hydroxycholesterol concentrations within a ± 50% range of the calculated average. In 
the second survey eleven different laboratories participated of which eight contributed to both 
surveys. The mean 24(S)-hydroxycholesterol concentration determined by all eleven 
participants were calculated for sample C (61.0±36.7 ng/mL; CV 60.3%) and D (38.0±21.6 
ng/mL; CV 56.8%). In the second survey one laboratory used GC-MS-epi, and six used GC-
MS-deuterium methods. Four laboratories provided results obtained from LC-MS-deuterium 
methods. Of the eleven participants, one who used LC-MS-deuterium method did not 
determine 24(S)-hydroxycholesterol concentrations within a ± 50% range of the calculated 
average. 
The results of 24(S)-hydroxycholesterol from the first and second survey are shown in figure 
1 A (Samples a and b are identified as outliers, sample c submitted inconsistent values) and 
figure 1B (Sample a is identified as outlier, sample a, b and c submitted inconsistent values) 





In the first survey for chromatographically determined 27-hydroxycholesterol nine different 
laboratories participated. The mean 27-hydroxycholesterol concentration determined by all 
nine participants was calculated for sample A (107.3±38.8 ng/mL; CV 36.2%) and B 
(121.7±43.6 ng/mL; CV 35.8%). One laboratory used GC-MS-epi and five used GC-MS-
deuterium methods. Three laboratories provided results obtained by LC-MS methods using 
deuterated sterols as internal standard. Two of the participants using GC-MS-deuterium and 
LC-MS-deuterium, did not determine 27-hydroxycholesterol concentrations within a ±50% 
range of the calculated average. 
 In the second survey eleven different laboratories participated from which eight contributed 
to both surveys. The mean 27-hydroxycholesterol concentration determined by all eleven 
participants was calculated for sample C (159.5±90.4 ng/mL; CV 56.6%) and D (162.6±97.2 
ng/mL; CV 59.8%). In the second survey one laboratory used GC-MS-epi, and six used GC-
MS-deuterium methods. Four laboratories provided results obtained by LC-MS-deuterium 
methods. Three of the participants, using GC-MS-epi and LC-MS-deuterium did not 
determine 27-hydroxycholesterol concentrations within a ±50% range of the calculated 
average. 
The results of 27-hydroxycholesterol from the first and second survey are shown in Figure 1 
C (samples a and b are identified as outlier) and Figure 1 D (samples a to c are identified as 
outlier, sample a and c submitted inconsistent values) and values for all subgroups are listed 





In the first survey seven different laboratories participated. The mean 7α-hydroxycholesterol 
concentration determined by all seven participants were calculated for sample A (427.8±261.3 
ng/mL; CV 61.1%) and B (1918.7±3793.2 ng/mL; CV 197.7%). Among all laboratories five 
used GC-MS-deuterium methods and one laboratory provided results obtained from LC-MS 
methods using deuterated sterols as internal standard. The seventh laboratory using GC-MS 
with 19-hydroxcholesterol as internal standard was omitted from the survey because of very 
high concentrations of 610 ng/mL and 10500 ng/mL for sample A and B, respectively. After 
exclusion of this participant the mean 7α-hydroxycholesterol were calculated for sample A 
(397.5.8±272.4 ng/mL; CV 68.5%) and B (488.4±289.2 ng/mL; CV 59.2%). In the second 
survey eight different laboratories participated among which five contributed to both surveys. 
The mean 7α-hydroxycholesterol concentrations determined by all eight participants were 
calculated for sample C (86.1±40.7 ng/mL; CV 47.2%) and D (83.9±62.3 ng/mL; CV 74.2%). 
In the second survey six laboratories used GC-MS-deuterium methods. Two laboratories 
provided results obtained by LC-MS-deuterium methods.  
The results of 7α-hydroxycholesterol from the first and second survey are shown in Figure 1 
E and Figure 1 F, respectively, and values for all subgroups are listed in detail in Table 2. 
 
4.6 Ratio 24(S)-hydroxycholesterol to 27-hydroxycholesterol 
Since the ratio of 24(S)-hydroxycholesterol to 27-hydroxycholesterol has reached importance 
in clinical diagnosis for the integrity of the blood-brain barrier and description of the state of 
neurological diseases we calculated this ratio for sample A to D for all participants. We 
accepted a difference of +/- 50% in each sample. Four participants in both survey did not 
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submit values. The average value of all participants and the identified outliers (bold) are listed 






The survey can be regarded as an attempt to explain the marked differences in concentrations 
of ring and side-chain oxidized cholesterols reported in literature. A multitude of different 
variants of gas- and liquid-chromatographic methods have been used in different reported 
studies. Our group initiated the first survey for chromatographic OCS (7α-, 24(S)-, 27-
hydroxycholesterol) determination by different laboratories in order to compare different 
methods and try to identify possible sources of errors. It must be emphasized that the 
determination of OCS species in human serum is associated with numerous potential sources 
of errors which may bias reported oxysterol concentrations in research articles or even worse 
in connection with diagnosis and patient care.  
In the first survey, 24(S)-hydroxycholesterol levels determined by laboratories using LC-MS-
deuterium revealed higher coefficients of variation than levels obtained with GC-MS-
deuterium methods (68.7-73.3% vs. 58.8-49.2%). Conversely, 27-hydroxycholesterol values 
determined by laboratories using LC-MS-deuterium methods revealed slightly lower 
coefficients of variation than reported with GC-MS-deuterium methods (23.2-25.4% vs. 35.1-
38.2%). However, the above coefficients of variation do not reflect the wide distribution of 
the reported values. As shown in Figure 1 single laboratories had difficulties to get consistent 
results or reported substantially higher values than the other laboratories. These substantially 
higher levels were regarded as outliers here. In the second interventional survey the 
participants were requested to quantify their sample concentrations against a provided 
standard solution to evaluate the influence of the calibration curve on the results. For 24(S)-
hydroxycholesterol CV values determined by GC-MS-deuterium methods are lower than in 
the first survey. The already good results for 27-hydroxcholesterol from the first survey have 
also been enhanced by the use of common calibration solution. The results of the participants 
in both ring trials did improve by using a common standard solution.  
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The ratio of plasma or csf 24S- to 27-hydroxycholesterol is often used as marker of blood-
brain barrier integrity or a marker for the state of neurological diseases [17, 18]. We here 
present the absolute values of 24S- and 27-hydroxycholesterin in Table 1 A-D and the ratios 
of both in Table 3. Interestingly, in one participant (#11, Table 3), we do receive 
unconspicous ratios in comparison to the ratios from other participants. However, in Figure 1 
the absolute values of this participant appear as outliers. The reason for this could be that the 
levels from the standard curves for both 24S- and 27-hydroxycholesterol are equally increased 
or decreased. Thus, it is of importance for further publication to show the basic individual 
oxysterol levels before calculating ratios. In case that only the data from a standard curve for 
24S-hydroxycholesterol are too high and those for 27-hydroxycholesterol are normal or too 
low, the ratio 24S- to 27-hydroxycholesterol could give us a wrong impression of the real 
state of the blood-brain barrier or a neurological disease.  
Since the samples were not specifically prepared to prevent cholesterol autoxidation during 
the lyophilisation process, storage nor shipping, the levels of 7α-hydroxycholesterol were 
widely distributed in the sample. Therefore, a clear statement about the 7α-hydroxycholesterol 
cannot be made.  
However, it must be noted that also here the use of a common standard appears to reduce the 
variation of the reported results and brought values together. Therefore, we conclude that even 
when using individual sample work-up procedures and different analytical methods similar 
results could be obtained when common quantified stock solutions are used. 
Despite this it is evident that some laboratories do have problems with measurement 
consistence and/or absolute quantification.  For LC-MS methods it is crucial to use internal 
standard compounds of the same chemical constitution co-eluting with the analyte. Therefore, 
corresponding deuterated oxysterols are necessary for a precise absolute quantification of 
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OCS. In most instances, the participants in this survey did not use the isotope labelled internal 
standard. The results of both surveys show how extremely the reported concentrations could 
vary between individual laboratories. 
6. Conclusions and outlook 
Comparing the results obtained with different analytical methods and with use of common 
standard solutions we conclude that the present state for the quantification of oxysterols from 
serum or plasma samples is quite unsatisfactory. We acknowledge that our pre-analytical 
protocol was not optimal and that variation in quantification could equally well be a 
consequence of hydrolysis methods used, independent of LC- of GC-MS measurement.  
We do need further attempts to harmonize our different analytical methods in order to 
compare OCS levels in individual subjects.  
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Table 1: List of methodological parameters during work-up within the different 
laboratories and of the analytical instruments used. 
 
sample volume [µL] 25; 100; 200; 400; 500; 1000 
internal standards [ng] 2; 5; 10; 15; 20; 35.74; 50; 100; 150; (or 2µmol) 
hydrolysis time [min] 20; 60; 120; 180 
hydrolysis temperature [°C] room temperature; 25; 60; 75 
hydrolysis NaOH/KOH concentration [mol/L] 0.35; 0.5; 0.71; 1.0; (or 50%) 
extraction solvents hexane; chloroforme; cyclohexane; isooctane;  
chloroforme: methanol (2:1) 
solvent volume for extraction [mL] 2; 3; 5; 7.2; 9; 18 
silylation time [min] 30 
silylation temperature [°C] 60 
silylation reagents (GC only) 
HMDS/TMCS/pyridine (3:1:9)(Supelco) 
BSTFA/TMCS 99:1 + pyridine 
HMDS/TMCS/Pyridine 2:1:3 
MSTFA: Pyridin (2:1) 1% TMCS 
reconstitution volume [µL] 50; 70; 300; 1400 
Injection volume [µL] 1; 2; 20; 40; 50 
split mode injection (GC only)  splitless 
column lenght (GC only) [m] 30; 50 (5cm and 25cm for LC systems) 
column diameter 250µm; 2.1mm; 4.6 mm 
film thickness 0.25µm; 5µm 
column film thickness (GC only) [µm] 0.1; 0.25 
columns (GC only) 
HP-5MS 
Hypersil Gold RP 
DB-5-MS 
revers phase C18 Supercoil LC18S  
C18 HPLC Zorbax Eclips plus C18 guard column c1   
HP-5MS 5% phenylmethyl siloxane 
separation instruments  
GC-Agilent Technologies 6890N 
Shimadzu GC-MSQP2010 
LC/MS model LC2010A Shimadzu 
detectors 
LTQ orbitrap XL  
LTQ-orbitrap Velos MS  
AgilentMS 5973N 
LCMS-2010A mass spectrometer with APCI interph  
SCIEX API 3000 triple quadrupol Photospray 
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Table 2: Results of 7α-, 24(S)-, and 27-hydroxcholesterol submitted by GC-MS and LC-MS methods in the first descriptive and second 
interventional survey. 
 First survey  Second survey     
                               
 Sample A Sample B  Sample C  Sample D  Participants 











trial  mean ± SD
1) CV2) min3) max4) mean ± SD1) CV2) min3) max4)  mean ± SD
1) CV2) min3) max4)  mean ± SD
1) CV2) min3) max4)  
total                               
24(S)-OH-
cholesterol 61.5 ± 36.0 58.5% 24.4 120.0 59.0 ± 43.3 73.3% 15.8 150.0  61.0 ± 36.7 60.3% 17.7 161.9  38.0 ± 21.6 56.8% 20.2 99.0  9 11 8 
GC-MS (total) 58.3 ± 30.1 51.6% 24.4 108.0 47.5 ± 21.1 44.4% 15.8 72.5  50.5 ± 16.8 33.2% 17.7 68.0  33.7 ± 9.0 26.6% 20.2 44.3  6 7 5 
GC-MS (epi) 76.4    64.3     68.0     44.3     1 1 1 
GC-MS (deuterium) 54.6 ± 32.1 58.8% 24.4 108.0 44.2 ± 21.7 49.2% 29.2 72.5  47.5 ± 16.3 34.2% 17.7 62.0  31.9 ± 8.4 26.2% 20.2 42.9  5 6 4 
LC-MS (deuterium) 68.1 ± 46.8 68.7% 29.2 120.0 82.0 ± 60.1 73.3% 36.0 150.0  79.3 ± 56.9 71.7% 40.3 161.9  45.5 ± 35.7 78.4% 25.9 99.0  3 4 3 
                               
total                               
27-OH-cholesterol 107.3 ± 38.8 36.2% 47.3 170.0 121.7 ± 43.6 35.8% 51.6 190.0  159.5 ± 90.4 56.6% 84.0 349.0  162.6 ± 97.2 59.8% 91.0 398.6  9 11 8 
GC-MS (total) 90.8 ± 31.8 35.1% 47.3 129.0 109.0 ± 43.6 40.0% 51.6 164.0  129.7 ± 43.4 33.4% 84.0 217.4  153.9 ± 109.3 71.0% 91.0 398.6  6 7 5 
GC-MS (epi) 68.3    72.4     217.4     398.6     1 1 1 
GC-MS (deuterium) 95.3 ± 33.4 35.1% 47.3 129.0 116.3 ± 44.5 38.2% 51.6 164.0  115.1 ± 21.6 18.7% 84.0 142.2  113.1 ± 18.9 16.7% 91.0 139.4  5 6 4 
LC-MS (deuterium) 140.2 ± 32.5 23.2% 105.6 129.0 147.2 ± 37.3 25.4% 121.5 164.0  211.6 ± 133.3 63.0% 95.6 349.0  177.9 ± 84.3 47.4% 104.7 284.0  3 4 3 
                               
total                               
7α-OH-cholesterol 397.5 ± 272.4 68.5% 77.5 884.0 488.4 ± 289.3 59.2% 99.4 844.0  86.1 ± 40.7 47.2% 40.3 164.0  83.9 ± 62.3 74.2% 17.0 196.8  6 8 5 
GC-MS (deuterium) 429.7 ± 291.5 67.9% 77.5 884.0 534.3 ± 298.0 55.8% 99.6 844.0  68.4 ± 23.7 34.7% 40.3 102.1  56.0 ± 36.8 65.7% 17.0 120.3  5 6 4 
LC-MS (deuterium) 236.5   236.5 236.5 259.5   259.5 259.5   139.4 ± 34.7 24.9% 114.9 164.0   167.6 ± 41.2 24.6% 138.5 196.8   1 2 1 
1) mean value with standard deviation [ng/mL]  




Table 3 Ratios of 24(S) to 27-hydroxycholesterol from individual  
laboratories as measured in the first (A, B) and second (C,D) trial. 
 
  Ratio 24(S)- to 27-OH-cholesterol 
Participant A   B   C   D 
1 0.45  0.44  0.45  0.26 
2 1.12  0.89  0.31  0.11 
3 0.51  0.59  0.50  0.39 
4 0.90  0.11      
5      0.52  0.40 
6 0.28  0.30  0.44  0.28 
7      0.14  0.18 
8      0.42  0.22 
9 0.71  0.79  0.21  0.13 
10 0.55  0.54  0.51  0.26 11 0.38  0.46  0.53  0.35 
12 0.39   0.39   0.41   0.25 
mean 0.59  0.50  0.40  0.26 
SD 0.27  0.24  0.13  0.09 CV [%] 46.5%  47.4%  32.3%  36.9% upper cut off 0.88  0.75  0.61  0.39 
lower cut off 0.29   0.25   0.20   0.13 
Data given in bold are outliers below or above the 50% cut-off levels. 






Distribution of 24S-,27-, and 7α-hydroxcholesterol concentrations analyzed by GC-MS and 
LC-MS methods in the first descriptive and second interventional survey. Values a, b, and c in 
the figures A, B, C, and D are regarded as outliers or inconsistent sample analysis. 
 
